



pcDNA™3.1(+)
pcDNA™3.1(-)

Catalog nos. V790-20 and V795-20

Version J
5 August 2008
28-0104

User Manual

Table of Contents

Important Information.....	v
Accessory Products	vi
Methods	1
Overview	1
Cloning into pcDNA™3.1	2
Transfection.....	6
Creating Stable Cell Lines	7
Appendix.....	10
pcDNA™3.1 Vectors	10
pcDNA™3.1/CAT.....	12
Technical Support.....	13
Purchaser Notification	13
References.....	15

Important Information

pcDNA™ Vectors

This manual is supplied with the following products.

Product	Catalog no.
pcDNA™3.1(+) Vector	V790-20
pcDNA™3.1(-) Vector	V795-20

Shipping and Storage

Vectors are shipped on wet ice. Upon receipt, store at -20°C.

Contents

The pcDNA™3.1 vector components pcDNA™3.1 are listed below:

Item	Concentration	Volume
pcDNA™3.1 Vector pcDNA™3.1(+) or pcDNA™3.1(-)	20 µg at 0.5 µg/µl, in TE buffer, pH 8.0 (10 mM Tris-HCl, 1 mM EDTA, pH 8.0)	40 µl
Control Plasmid pcDNA™3.1/CAT	20 µg at 0.5 µg/µl, in TE buffer, pH 8.0 (10 mM Tris-HCl, 1 mM EDTA, pH 8.0)	40 µl

Product Qualification

The Certificate of Analysis provides detailed quality control information for each product. Certificates of Analysis are available on our website. Go to www.invitrogen.com/support and search for the Certificate of Analysis by product lot number, which is printed on the box.

Accessory Products

Additional Products

Additional products that may be used with the pcDNA[™]3.1 vectors are available from Invitrogen. Ordering information is provided below.

Product	Amount	Catalog no.
One Shot [®] TOP10 Chemically Competent Cells	10 reactions	C4040-10
	20 reactions	C4040-03
One Shot [®] TOP10F' Chemically Competent Cells	20 reactions	C3030-03
	40 reactions	C3030-06
Lipofectamine [™] 2000	1.5 ml	11668-019
	0.75 ml	11668-027
Geneticin [®]	1 g	11811-023
	5 g	11811-031
PureLink [™] HQ Mini Plasmid Purification Kit	100 preps	K2100-01
PureLink [™] HiPure Plasmid Midiprep Kit	25 preps	K2100-04

Methods

Overview

Description pcDNATM3.1(+) and pcDNATM3.1(-) are 5.4 kb vectors derived from pcDNATM3 and designed for high-level stable and transient expression in mammalian hosts. High-level stable and non-replicative transient expression can be carried out in most mammalian cells. The vectors contain the following elements:

- Human cytomegalovirus immediate-early (CMV) promoter for high-level expression in a wide range of mammalian cells
- Multiple cloning sites in the forward (+) and reverse (-) orientations to facilitate cloning
- Neomycin resistance gene for selection of stable cell lines
- Episomal replication in cells lines that are latently infected with SV40 or that express the SV40 large T antigen (e.g. COS-1, COS-7)

The control plasmid, pcDNATM3.1/CAT, is included for use as a positive control for transfection and expression in the cell line of choice.

Experimental Outline Use the following outline to clone and express your gene of interest in pcDNATM3.1.

1. Consult the multiple cloning sites described on pages 3-4 to design a strategy to clone your gene into pcDNATM3.1.
2. Ligate your insert into the appropriate vector and transform into *E. coli*. Select transformants on LB plates containing 50–100 µg/ml ampicillin.
3. Analyze your transformants for the presence of insert by restriction digestion.
4. Select a transformant with the correct restriction pattern and use sequencing to confirm that your gene is cloned in the proper orientation.
5. Transfect your construct into the mammalian cell line of interest using your own method of choice. Generate a stable cell line, if desired.
6. Test for expression of your recombinant gene by western blot analysis or functional assay.

Cloning into pcDNATM3.1

Introduction

Diagrams are provided on pages 3-4 to help you design a cloning strategy for ligating your gene of interest into pcDNATM3.1. General considerations for cloning and transformation are listed below.

General Molecular Biology Techniques

For help with DNA ligations, *E. coli* transformations, restriction enzyme analysis, purification of single-stranded DNA, DNA sequencing, and DNA biochemistry, please refer to *Molecular Cloning: A Laboratory Manual* (Sambrook *et al.*, 1989) or *Current Protocols in Molecular Biology* (Ausubel *et al.*, 1994).

E. coli Strain

Many *E. coli* strains are suitable for the propagation of this vector including TOP10F', DH5TM-T1^R, and TOP10. We recommend that you propagate vectors containing inserts in *E. coli* strains that are recombination deficient (*recA*) and endonuclease A-deficient (*endA*).



Note

If you wish to express a human gene of interest from pcDNATM3.1, we recommend using an UltimateTM Human ORF (hORF) Clone available from Invitrogen. For more information about the UltimateTM hORF Clones available, refer to our Web site (www.invitrogen.com) or contact Technical Support (page 13).

Transformation Method

You may use any method of your choice for transformation. Chemical transformation is the most convenient for most researchers. Electroporation is the most efficient and the method of choice for large plasmids.

Maintenance of pcDNATM3.1

To propagate and maintain pcDNATM3.1, use 10 ng of vector to transform a *recA*, *endA* *E. coli* strain like TOP10F', DH5TM-T1^R, TOP10, or equivalent. Select transformants on LB plates containing 50–100 µg/ml ampicillin. Be sure to prepare a glycerol stock of your plasmid-containing *E. coli* strain for long-term storage (see page 5).

Cloning Considerations

pcDNATM3.1(+) and pcDNATM3.1(–) are non-fusion vectors. Your insert should contain a Kozak translation initiation sequence with an ATG initiation codon for proper initiation of translation (Kozak, 1987; Kozak, 1991; Kozak, 1990). An example of a Kozak consensus sequence is provided below. Other sequences are possible, but the G or A at position –3 and the G at position +4 (shown in bold) illustrates the most commonly occurring sequence with strong consensus. Replacing one of the two bases at these positions provides moderate consensus, while having neither results in weak consensus. The ATG initiation codon is shown underlined.

(G/A)NNATGG

Your insert must also contain a stop codon for proper termination of your gene. Please note that the *Xba* I site contains an internal stop codon (TCTAGA).

continued on next page

Cloning into pcDNA™3.1, continued

Multiple Cloning Site of pcDNA™3.1(-)

Below is the multiple cloning site for pcDNA™3.1(-). Restriction sites are labeled to indicate the cleavage site. The *Xba* I site contains an internal stop codon (TCTAGA). The multiple cloning site has been confirmed by sequencing and functional testing. **The complete sequence of pcDNA™3.1(-) is available for downloading from our web site (www.invitrogen.com) or from Technical Support (see page 13).** For a map and a description of the features of pcDNA™3.1(-), please see the **Appendix**, pages 10-11.

```

          enhancer region (3' end)
          |
689  CATTGACGTC AATGGGAGTT TGT TTTGGCA CAAAATCAA CGGGACTTTC CAAAATGTCG
          |
          CAAT
          |
749  TAACA AACTCC GCCCATTGA CGCAAATGGG CGGTAGGCGT GTACGGTGGG AGGTCTATAT
          |
          3' end of hCMV
          |
          putative transcriptional start
          |
809  AAGCAGAGCT CTCTGGCTAA CTAGAGAACC CACTGCTTAC TGGCTTATCG AAATTAATAC
          |
          T7 promoter/primer binding site
          |
869  GACTCACTAT AGGGAGACCC AAGCTGGCTA GCGTTTAAAC GGGCCCTCTA GACTCGAGCG
          |
          BstX I*   EcoR V   EcoR I   BstX I*   BamH I
          |       |       |       |       |
929  GCCGCCACTG TGCTGGATAT CTGCAGAATT CCACCACACT GGACTAGTGG ATCCGAGCTC
          |
          Asp718 I  Kpn I  Hind III  Afl II   Pme I
          |       |       |       |       |
989  GGTACCAAGC TTAAGTTTAA ACCGCTGATC AGCCTCGACT GTGCCTTCTA GTTGCCAGCC
          |
          pcDNA3.1/BGH reverse priming site
          |
1049 ATCTGTTGTT TGCCCTCCC CCGTGCCTTC CTTGACCCTG GAAGGTGCCA CTCCCACTGT
          |
          BGH poly (A) site
          |
1109 CCTTTCCTAA TAAAATGAGG AAATTGCATC
  
```

*Please note that there are two *BstX* I sites in the polylinker.

Cloning into pcDNA™3.1, continued

E. coli **Transformation**

Once you have obtained a clone containing your gene of interest, you may transform the clone into a suitable *E. coli* host (see below). We recommend including a negative control in your experiment to help you evaluate your results.



We recommend that you sequence your construct with the T7 Promoter and BGH Reverse primers (Catalog nos. N560-02 and N575-02, respectively) to confirm that your gene is in the correct orientation for expression and contains an ATG and a stop codon. Please refer to the diagrams on pages 3-4 for the sequences and location of the priming sites. The primers are available separately from Invitrogen in 2 µg aliquots.

Preparing a **Glycerol Stock**

Once you have identified the correct clone, purify the colony and make a glycerol stock for long-term storage. You should keep a DNA stock of your plasmid at –20°C.

- Streak the original colony out on an LB plate containing 50 µg/ml ampicillin. Incubate the plate at 37°C overnight.
- Isolate a single colony and inoculate into 1–2 ml of LB containing 50 µg/ml ampicillin.
- Grow the culture to mid-log phase ($OD_{600} = 0.5\text{--}0.7$).
- Mix 0.85 ml of culture with 0.15 ml of sterile glycerol and transfer to a cryovial.

Store at –80°C.

continued on next page

Transfection

Introduction

Once you have verified that your gene is cloned in the correct orientation and contains an initiation ATG and a stop codon, you are ready to transfect your cell line of choice. We recommend that you include the positive control vector and a mock transfection (negative control) to evaluate your results.

Plasmid Preparation

Once you have generated your expression clone, you must isolate plasmid DNA for transfection. Plasmid DNA for transfection into eukaryotic cells must be clean and free contamination with from phenol and sodium chloride. Contaminants will kill the cells, and salt will interfere with lipid complexing, decreasing transfection efficiency. We recommend isolating plasmid DNA using the PureLink™ HQ Mini Plasmid Purification Kit (Catalog no. K2100-01), the PureLink™ HiPure Plasmid Midiprep Kit (Catalog no. K2100-04), or CsCl gradient centrifugation.

Methods of Transfection

For established cell lines (*e.g.* HeLa), consult original references or the supplier of your cell line for the optimal method of transfection. We recommend that you follow exactly the protocol for your cell line. Pay particular attention to medium requirements, when to pass the cells, and at what dilution to split the cells. Further information is provided in *Current Protocols in Molecular Biology* (Ausubel *et al.*, 1994).

Methods for transfection include calcium phosphate (Chen and Okayama, 1987; Wigler *et al.*, 1977), lipid-mediated (Felgner *et al.*, 1989; Felgner and Ringold, 1989) and electroporation (Chu *et al.*, 1987; Shigekawa and Dower, 1988). For high efficiency transfection in a broad range of mammalian cell lines, we recommend using Lipofectamine™ 2000 Reagent (Catalog no. 11668-027) available from Invitrogen. For more information about Lipofectamine™ 2000 and other transfection reagents, refer to our Web site (www.invitrogen.com) or contact Technical Support (page 13).

Positive Control

pcDNA™3.1/CAT is provided as a positive control vector for mammalian transfection and expression (see page 12) and may be used to optimize transfection conditions for your cell line. The gene encoding chloramphenicol acetyl transferase (CAT) is expressed in mammalian cells under the control of the CMV promoter. A successful transfection will result in CAT expression that can be easily assayed (see below).

Assay for CAT Protein

You may assay for CAT expression by ELISA assay, western blot analysis, fluorometric assay, or radioactive assay (Ausubel *et al.*, 1994; Neumann *et al.*, 1987). If you wish to detect CAT protein using western blot analysis, you may use the Anti-CAT Antiserum (Catalog no. R902-25) available from Invitrogen. Other kits to assay for CAT protein using ELISA assay are available from Roche Molecular Biochemicals (Catalog no. 1 363 727) and Molecular Probes (Catalog no. F-2900).

continued on next page

Creating Stable Cell Lines

Introduction

The pcDNA™3.1(+) and pcDNA™3.1(-) vectors contain the neomycin resistance gene for selection of stable cell lines using neomycin (Geneticin®). We recommend that you test the sensitivity of your mammalian host cell to Geneticin® as natural resistance varies among cell lines. General information and guidelines are provided in this section for your convenience.



To obtain stable transfectants, we recommend that you linearize your pcDNA™3.1 construct before transfection. While linearizing the vector may not improve the efficiency of transfection, it increases the chances that the vector does not integrate in a way that disrupts elements necessary for expression in mammalian cells. To linearize your construct, cut at a unique site that is not located within a critical element or within your gene of interest.

Geneticin®

Geneticin® blocks protein synthesis in mammalian cells by interfering with ribosomal function. It is an aminoglycoside, similar in structure to neomycin, gentamycin, and kanamycin. Expression in mammalian cells of the bacterial aminoglycoside phosphotransferase gene (APH), derived from Tn5, results in detoxification of Geneticin® (Southern and Berg, 1982).

Determining Antibiotic Sensitivity

To successfully generate a stable cell line expressing your protein of interest, you need to determine the minimum concentration of Geneticin® required to kill your untransfected host cell line. Test a range of concentrations (see protocol below) to ensure that you determine the minimum concentration necessary for your cell line.

1. Plate or split a confluent plate so the cells will be approximately 25% confluent. Prepare a set of 6–7 plates. Add the following concentrations of antibiotic to each plate:
 - For Geneticin® selection, test 0, 50, 125, 250, 500, 750, and 1000 µg/ml Geneticin®.
 2. Replenish the selective media every 3–4 days, and observe the percentage of surviving cells.
 3. Count the number of viable cells at regular intervals to determine the appropriate concentration of antibiotic that prevents growth within 1–3 weeks after addition of the antibiotic.
-

Geneticin® Selection Guidelines

Once you have determined the appropriate Geneticin® concentration to use for selection, you can generate a stable cell line expressing your pcDNA™3.1 construct. Geneticin® is available separately from Invitrogen (see page vi for ordering information). Use as follows:

1. Prepare Geneticin® in a buffered solution (*e.g.* 100 mM HEPES, pH 7.3).
 2. Use the predetermined concentration of Geneticin® in complete medium.
 3. Calculate concentration based on the amount of active drug.
 4. Cells will divide once or twice in the presence of lethal doses of Geneticin®, so the effects of the drug take several days to become apparent. Complete selection can take from 2 to 3 weeks of growth in selective medium.
-

continued on next page

Creating Stable Cell Lines, continued

Possible Sites for Linearization of pcDNA3.1(+)

Prior to transfection, we recommend that you linearize the pcDNA™3.1(+) vector. Linearizing pcDNA™3.1(+) will decrease the likelihood of the vector integrating into the genome in a way that disrupts the gene of interest or other elements required for expression in mammalian cells. The table below lists unique restriction sites that may be used to linearize your construct prior to transfection. **Other unique restriction sites are possible.** Be sure that your insert does not contain the restriction enzyme site you wish to use to linearize your vector.

Enzyme	Restriction Site (bp)	Location	Supplier
<i>Bgl</i> II	12	Upstream of CMV promoter	Invitrogen, Catalog no. 15213-028
<i>Mfe</i> I	161	Upstream of CMV promoter	New England Biolabs
<i>Bst</i> 1107 I	3236	End of SV40 polyA	AGS*, Fermentas, Takara, Roche Mol. Biochemicals
<i>Eam</i> 1105 I	4505	Ampicillin gene	AGS*, Fermentas, Takara
<i>Pvu</i> I	4875	Ampicillin gene	Invitrogen, Catalog no. 25420-019
<i>Sca</i> I	4985	Ampicillin gene	Invitrogen, Catalog no. 15436-017
<i>Ssp</i> I	5309	<i>bla</i> promoter	Invitrogen, Catalog no. 15458-011

*Angewandte Gentechnologie Systeme

Possible Sites for Linearization of pcDNA™3.1(-)

The table below lists unique restriction sites that may be used to linearize your pcDNA™3.1(-) construct prior to transfection. **Other unique restriction sites are possible.** Be sure that your insert does not contain the restriction enzyme site you wish to use to linearize your vector.

Enzyme	Restriction Site (bp)	Location	Supplier
<i>Bgl</i> II	12	Upstream of CMV promoter	Invitrogen, Catalog no. 15213-028
<i>Mfe</i> I	161	Upstream of CMV promoter	New England Biolabs
<i>Bst</i> 1107 I	3235	End of SV40 polyA	AGS*, Fermentas, Takara, Roche Mol. Biochemicals
<i>Eam</i> 1105 I	4504	Ampicillin gene	AGS*, Fermentas, Takara
<i>Pvu</i> I	4874	Ampicillin gene	Invitrogen, Catalog no. 25420-019
<i>Sca</i> I	4984	Ampicillin gene	Invitrogen, Catalog no. 15436-017
<i>Ssp</i> I	5308	<i>bla</i> promoter	Invitrogen, Catalog no. 15458-011

*Angewandte Gentechnologie Systeme

continued on next page

Creating Stable Cell Lines, continued

Selection of Stable Integrants

Once you have determined the appropriate Geneticin® concentration to use for selection in your host cell line, you can generate a stable cell line expressing your gene of interest.


1. Transfect your mammalian host cell line with your pcDNA™3.1 construct using the desired protocol. Remember to include a plate of untransfected cells as a negative control and the pcDNA™3.1/CAT plasmid as a positive control.
 2. 24 hours after transfection, wash the cells and add fresh medium to the cells.
 3. 48 hours after transfection, split the cells into fresh medium containing Geneticin® at the pre-determined concentration required for your cell line. Split the cells such that they are no more than 25% confluent.
 4. Feed the cells with selective medium every 3–4 days until Geneticin®-resistant foci can be identified.
 5. Pick and expand colonies in 96- or 48-well plates.
-

Appendix

pcDNA™3.1 Vectors

Map

The figure below summarizes the features of the pcDNA™3.1(+) and pcDNA™3.1(-) vectors. **The complete sequences for pcDNA™3.1(+) and pcDNA™3.1(-) are available for down-loading from our World Wide Web site (www.invitrogen.com) or from Technical Support (see page 13).** Details of the multiple cloning sites are shown on page 3 for pcDNA™3.1(+) and page 4 for pcDNA™3.1(-).



Comments for pcDNA3.1 (+)

5428 nucleotides

- CMV promoter: bases 232-819
- T7 promoter/priming site: bases 863-882
- Multiple cloning site: bases 895-1010
- pcDNA3.1/BGH reverse priming site: bases 1022-1039
- BGH polyadenylation sequence: bases 1028-1252
- f1 origin: bases 1298-1726
- SV40 early promoter and origin: bases 1731-2074
- Neomycin resistance gene (ORF): bases 2136-2930
- SV40 early polyadenylation signal: bases 3104-3234
- pUC origin: bases 3617-4287 (complementary strand)
- Ampicillin resistance gene (*bla*): bases 4432-5428 (complementary strand)
- ORF: bases 4432-5292 (complementary strand)
- Ribosome binding site: bases 5300-5304 (complementary strand)
- bla* promoter (P3): bases 5327-5333 (complementary strand)

continued on next page

pcDNA™3.1 Vectors, continued

Features

pcDNA™3.1(+) (5428 bp) and pcDNA™3.1(-) (5427 bp) contain the following elements. All features have been functionally tested.

Feature	Benefit
Human cytomegalovirus (CMV) immediate-early promoter/enhancer	Permits efficient, high-level expression of your recombinant protein (Andersson <i>et al.</i> , 1989; Boshart <i>et al.</i> , 1985; Nelson <i>et al.</i> , 1987)
T7 promoter/priming site	Allows for <i>in vitro</i> transcription in the sense orientation and sequencing through the insert
Multiple cloning site in forward or reverse orientation	Allows insertion of your gene and facilitates cloning
Bovine growth hormone (BGH) polyadenylation signal	Efficient transcription termination and polyadenylation of mRNA (Goodwin and Rottman, 1992)
f1 origin	Allows rescue of single-stranded DNA
SV40 early promoter and origin	Allows efficient, high-level expression of the neomycin resistance gene and episomal replication in cells expressing SV40 large T antigen
Neomycin resistance gene	Selection of stable transfectants in mammalian cells (Southern and Berg, 1982)
SV40 early polyadenylation signal	Efficient transcription termination and polyadenylation of mRNA
pUC origin	High-copy number replication and growth in <i>E. coli</i>
Ampicillin resistance gene (β -lactamase)	Selection of vector in <i>E. coli</i>
Ampicillin (<i>bla</i>) resistance gene (β -lactamase)	Allows selection of transformants in <i>E. coli</i>


pcDNA™3.1/CAT

Description

pcDNA™3.1/CAT is a 6217 bp control vector containing the gene for CAT. It was constructed by digesting pcDNA™3.1(+) with *Xho* I and *Xba* I and treating with Klenow. An 800 bp *Hind* III fragment containing the CAT gene was treated with Klenow and then ligated into pcDNA™3.1(+).

Map

The figure below summarizes the features of the pcDNA™3.1/CAT vector. **The complete nucleotide sequence for pcDNA™3.1/CAT is available for downloading from our World Wide Web site (www.invitrogen.com) or by contacting Technical Support (see page 13).**



Technical Support

World Wide Web



Visit the Invitrogen website at www.invitrogen.com for:

- Technical resources, including manuals, vector maps and sequences, application notes, MSDSs, FAQs, formulations, citations, handbooks, etc.
- Complete technical support contact information
- Access to the Invitrogen Online Catalog

Additional product information and special offers

Contact Us

For more information or technical assistance, call, write, fax, or email. Additional international offices are listed on our Web page (www.invitrogen.com).

Corporate Headquarters:

Invitrogen Corporation
5791 Van Allen Way
Carlsbad, CA 92008 USA
Tel: 1 760 603 7200
Tel (Toll Free): 1 800 955 6288
Fax: 1 760 602 6500
E-mail: tech_support@invitrogen.com

Japanese Headquarters:

Invitrogen Japan K.K.
Nihonbashi Hama-Cho Park
Bldg. 4F
2-35-4, Hama-Cho, Nihonbashi
Tel: 81 3 3663 7972
Fax: 81 3 3663 8242
E-mail: jpinfo@invitrogen.com

European Headquarters:

Invitrogen Ltd
Inchinnan Business Park
3 Fountain Drive
Paisley PA4 9RF, UK
Tel: +44 (0) 141 814 6100
Tech Fax: +44 (0) 141 814 6117
E-mail: eurotech@invitrogen.com

MSDS

Material Safety Data Sheets (MSDSs) are available on our website at www.invitrogen.com/msds.

Certificate of Analysis

The Certificate of Analysis (CofA) provides detailed quality control information for each product. CofAs are available on our website at www.invitrogen.com/support, and are searchable by product lot number, which is printed on each box.

Limited Warranty

Invitrogen is committed to providing our customers with high-quality goods and services. Our goal is to ensure that every customer is 100% satisfied with our products and our service. If you should have any questions or concerns about an Invitrogen product or service, contact our Technical Support Representatives.

Invitrogen warrants that all of its products will perform according to specifications stated on the certificate of analysis. The company will replace, free of charge, any product that does not meet those specifications. This warranty limits Invitrogen Corporation's liability only to the cost of the product. No warranty is granted for products beyond their listed expiration date. No warranty is applicable unless all product components are stored in accordance with instructions. Invitrogen reserves the right to select the method(s) used to analyze a product unless Invitrogen agrees to a specified method in writing prior to acceptance of the order.

Invitrogen makes every effort to ensure the accuracy of its publications, but realizes that the occasional typographical or other error is inevitable. Therefore Invitrogen makes no warranty of any kind regarding the contents of any publications or documentation. If you discover an error in any of our publications, please report it to our Technical Support Representatives.

Invitrogen assumes no responsibility or liability for any special, incidental, indirect or consequential loss or damage whatsoever. The above limited warranty is sole and exclusive. No other warranty is made, whether expressed or implied, including any warranty of merchantability or fitness for a particular purpose.

continued on next page

Purchaser Notification

Introduction

Use of pcDNA™ 3.1 is covered under the licenses detailed below.

**Limited Use
Label License
No. 5:
Invitrogen
Technology**

The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. The buyer may transfer information or materials made through the use of this product to a scientific collaborator, provided that such transfer is not for any Commercial Purpose, and that such collaborator agrees in writing (a) not to transfer such materials to any third party, and (b) to use such transferred materials and/or information solely for research and not for Commercial Purposes. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. For products that are subject to multiple limited use label licenses, the most restrictive terms apply. Invitrogen Corporation will not assert a claim against the buyer of infringement of patents owned or controlled by Invitrogen Corporation which cover this product based upon the manufacture, use or sale of a therapeutic, clinical diagnostic, vaccine or prophylactic product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. If the purchaser is not willing to accept the limitations of this limited use statement, Invitrogen is willing to accept return of the product with a full refund. For information on purchasing a license to this product for purposes other than research, contact Licensing Department, Invitrogen Corporation, 5791 Van Allen Way, Carlsbad, California 92008. Phone (760) 603-7200. Fax (760) 602-6500. Email: outlicensing@invitrogen.com

**Limited Use
Label License
No. 28: CMV
Promoter**

The use of the CMV promoter is covered under U.S. Patent Nos. 5,168,062 and 5,385,839 owned and licensed by the University of Iowa Research Foundation and is sold for research use only. Commercial users must obtain a license to these patents directly from the University of Iowa Research Foundation (UIRF), 214 Technology Innovation Center, Iowa City, Iowa 52242. For further information, please contact the Associate Director of UIRF, at 319-335-4546.

**Limited Use
Label License
No. 49: BGH
Polyadenylation
Signal**

The bovine growth hormone (BGH) polyadenylation sequence is licensed under U.S. Patent No. 5,122,458 and foreign equivalents and is sold for the following purposes only:

Research purposes, which means uses directed to the identification of useful recombinant proteins and the investigation of the recombinant expression of proteins, which uses shall in no event include any of the following: any use in humans of a CLAIMED DNA or CLAIMED CELL; any use in human of protein or other substance expressed or made at any stage of its production with the use of a CLAIMED DNA or a CLAIMED CELL; any use in which a CLAIMED DNA or CLAIMED CELL would be sold or transferred to another party other than Invitrogen, its affiliate, or its sublicensee; any use in connection with the expression or production of a product intended for sale or commercial use; or any use for drug screening or drug development.

Use of the bgh polyadenylation signal found in this product in screening requires a license from Research Corporation Technologies, Inc. (RCT). If you do not already have the appropriate commercial license from RCT for this use, the bgh polyadenylation signal contained in this product cannot be used until a commercial license is obtained. After purchasing these materials from Invitrogen Corporation, if you do not have a commercial license from RCT, you must contact RCT within 30 days to obtain a commercial license.

Inquiries for commercial use should be directed to: David Bramhill, Research Corporation Technologies, 101 North Wilmot Road, Suite 600, Tucson, AZ 85711-3335, Tel: 1-520-748-4400 Fax: 1-520-748-0025.

continued on next page

References

- Andersson, S., Davis, D. L., Dahlbäck, H., Jörnvall, H., and Russell, D. W. (1989). Cloning, Structure, and Expression of the Mitochondrial Cytochrome P-450 Sterol 26-Hydroxylase, a Bile Acid Biosynthetic Enzyme. *J. Biol. Chem.* *264*, 8222-8229.
- Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K. (1994). *Current Protocols in Molecular Biology* (New York: Greene Publishing Associates and Wiley-Interscience).
- Boshart, M., Weber, F., Jahn, G., Dorsch-Häsler, K., Fleckenstein, B., and Schaffner, W. (1985). A Very Strong Enhancer is Located Upstream of an Immediate Early Gene of Human Cytomegalovirus. *Cell* *41*, 521-530.
- Chen, C., and Okayama, H. (1987). High-Efficiency Transformation of Mammalian Cells by Plasmid DNA. *Mol. Cell. Biol.* *7*, 2745-2752.
- Chu, G., Hayakawa, H., and Berg, P. (1987). Electroporation for the Efficient Transfection of Mammalian Cells with DNA. *Nuc. Acids Res.* *15*, 1311-1326.
- Felgner, P. L., Holm, M., and Chan, H. (1989). Cationic Liposome Mediated Transfection. *Proc. West. Pharmacol. Soc.* *32*, 115-121.
- Felgner, P. L., and Ringold, G. M. (1989). Cationic Liposome-Mediated Transfection. *Nature* *337*, 387-388.
- Goodwin, E. C., and Rottman, F. M. (1992). The 3'-Flanking Sequence of the Bovine Growth Hormone Gene Contains Novel Elements Required for Efficient and Accurate Polyadenylation. *J. Biol. Chem.* *267*, 16330-16334.
- Kozak, M. (1987). An Analysis of 5'-Noncoding Sequences from 699 Vertebrate Messenger RNAs. *Nuc. Acids Res.* *15*, 8125-8148.
- Kozak, M. (1991). An Analysis of Vertebrate mRNA Sequences: Intimations of Translational Control. *J. Cell Biol.* *115*, 887-903.
- Kozak, M. (1990). Downstream Secondary Structure Facilitates Recognition of Initiator Codons by Eukaryotic Ribosomes. *Proc. Natl. Acad. Sci. USA* *87*, 8301-8305.
- Nelson, J. A., Reynolds-Kohler, C., and Smith, B. A. (1987). Negative and Positive Regulation by a Short Segment in the 5'-Flanking Region of the Human Cytomegalovirus Major Immediate-Early Gene. *Mol. Cell. Biol.* *7*, 4125-4129.
- Neumann, J. R., Morency, C. A., and Russian, K. O. (1987). A Novel Rapid Assay for Chloramphenicol Acetyltransferase Gene Expression. *BioTechniques* *5*, 444-447.
- Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989). *Molecular Cloning: A Laboratory Manual*, Second Edition (Plainview, New York: Cold Spring Harbor Laboratory Press).
- Shigekawa, K., and Dower, W. J. (1988). Electroporation of Eukaryotes and Prokaryotes: A General Approach to the Introduction of Macromolecules into Cells. *BioTechniques* *6*, 742-751.
- Southern, P. J., and Berg, P. (1982). Transformation of Mammalian Cells to Antibiotic Resistance with a Bacterial Gene Under Control of the SV40 Early Region Promoter. *J. Molec. Appl. Gen.* *1*, 327-339.
- Wigler, M., Silverstein, S., Lee, L.-S., Pellicer, A., Cheng, Y.-C., and Axel, R. (1977). Transfer of Purified Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cells. *Cell* *11*, 223-232.



Corporate Headquarters

Invitrogen Corporation

5791 Van Allen Way

Carlsbad, CA 92008

T: 1 760 603 7200

F: 1 760 602 6500

E: tech_support@invitrogen.com

For country-specific contact information, visit our web site at www.invitrogen.com